Evidence map›Paper›PMID 42292352›Full record

Trial reportFrontiers in immunology2026

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Derrick Robertson, Enrique Alvarez, Lawrence Steinman, Hans-Peter Hartung, Peiqing Qian, Krzysztof Selmaj, Sibyl Wray, Daniel Wynn, Edward J Fox, Koby Mok and 4 more

2 registry-linked trialsAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03277248 phase3completednot on this map

Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)

TypeinterventionalSponsorTG Therapeutics, Inc.Ran2017 to 2020Enrolled545ConditionsRelapsing Multiple Sclerosis (RMS)ArmsUblituximab, Teriflunomide, Oral Placebo, IV Placebo
NCT03277261 phase3completednot on this map

Phase III: UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)

TypeinterventionalSponsorTG Therapeutics, Inc.Ran2017 to 2020Enrolled549ConditionsRelapsing Multiple Sclerosis (RMS)ArmsUblituximab, Teriflunomide, Oral Placebo, IV Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Derrick RobertsonUniversity of South Florida, Tampa, FL, United States.
Enrique AlvarezUniversity of Colorado, Aurora, CO, United States.
Lawrence SteinmanStanford University, Stanford, CA, United States.
Hans-Peter HartungHeinrich Heine University Düsseldorf, Düsseldorf, Germany.
Peiqing QianSwedish Medical Center, Seattle, WA, United States.
Krzysztof SelmajCenter of Neurology, Lodz, Poland.
Sibyl WrayHope Neurology, Knoxville, TN, United States.
Daniel WynnConsultants in Neurology, Northbrook, IL, United States.
Edward J FoxTG Therapeutics, Morrisville, NC, United States.
Koby MokTG Therapeutics, Morrisville, NC, United States.
Hari P MiskinTG Therapeutics, Morrisville, NC, United States.
Yihuan XuTG Therapeutics, Morrisville, NC, United States.
Christopher A GarnerTG Therapeutics, Morrisville, NC, United States.
Bruce A C CreeUCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Evidence suggests that treating relapsing multiple sclerosis (RMS) initially with a high-efficacy disease-modifying therapy (DMT) is superior to an escalating approach at reducing disability progression and relapse rate. Objectives: To evaluate the efficacy of ublituximab versus teriflunomide in participants without prior DMT (treatment-naïve population) and in a subset of treatment-naïve participants with symptom onset ≤ three years (early treatment subpopulation). Methods: Pooled Results: The annualized relapse rate was 0.081 for ublituximab ( Conclusions: Ublituximab was associated with significant treatment benefits at Week 96 in treatment-naïve participants and those receiving treatment within three years of symptom onset. Clinical trial registration: https://clinicaltrials.gov/study/NCT03277261 and https://clinicaltrials.gov/study/NCT03277248, identifiers NCT03277261 and NCT03277248.

Indexed as

Antibodies, MonoclonalMultiple Sclerosis, Relapsing-RemittingAdultCrotonatesDisease ProgressionFemaleHumansHydroxybutyratesMaleMiddle AgedNitrilesToluidinesTreatment OutcomeAntibodies, MonoclonalCrotonatesHydroxybutyratesNitrilesteriflunomideToluidinesanti-CD20disease-modifying therapymonoclonal antibodiesmultiple sclerosistreatment naïveublituximab

Identifiers

PMID42292352
PMCPMC13260720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.